Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label follow-up study of VIPES to evaluate long-term efficacy and safety of Viaskin Peanut
2013-001754-10Phase 2Completed
- Sponsor
- DBV Technologies
- Start
- Oct 2013
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DBV712 Viaskin® in peanut allergy, sponsored by DBV Technologies. Primary endpoints: Long-term efficacy of Viaskin Peanut after up to 36 months of EPIT and Long-term safety of Viaskin Peanut. Started Oct 2013; status: completed.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2013-001754-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001754-10.